HRTX Q1 2025 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$162M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$39M+12.2% YoY

Gross Profit

$30M78.3% margin

Operating Income

$3M8.1% margin

Net Income

$3M6.8% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

-4.6%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$236M

Total Liabilities

$264M

Stockholders' Equity

-$28M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$39M	$35M	+12.2%
Gross Profit	$30M	$26M	+16.1%
Operating Income	$3M	-$5M	+165.7%
Net Income	$3M	-$3M	+183.4%

Revenue Segments

C I N V A N T I

$26M70%

Z Y N R E L E F

$8M22%

S U S T O L

$3M8%